Answers are grounded in this paper and cite their sources.
Pancreatic ductal adenocarcinoma (PDAC) is a leading cause of cancer-related mortality in the United States, highlighting the need for effective therapeutic strategies. Oxidative phosphorylation (OXPHOS) has emerged as a promising therapeutic target due to metabolic reprogramming and the pro-survival role of mitochondria in PDAC. The mitochondrial ClpXP complex, composed of the AAA+ ATPase ClpX and the peptidase ClpP, regulates mitochondrial homeostasis through protein degradation. Madera Therapeutics has developed novel ClpP activators, including TR-107. Here, we demonstrate that TR-107 reduces viability in four PDAC organoids and four cell lines at low-nanomolar concentrations while decreasing ClpX expression in a dose-dependent manner. Transcriptomic analysis revealed alterations in ferroptosis, amino acid metabolism, and HIF-1α signaling pathways. Notably, TR-107 retained its efficacy and mechanism of action under hypoxic conditions. Furthermore, TR-107 synergized with the AKT inhibitor capivasertib to suppress cell viability and modulate downstream signaling pathways. Collectively, these findings identify TR-107 as a promising therapeutic candidate that targets the mitochondrial ClpXP complex, disrupts mitochondrial function, and induces cellular stress and metabolic dysregulation. These effects may provide opportunities for combination therapies to improve treatment outcomes in PDAC.
No takes yet. Share an insight, caveat, or question.
LaComb et al. (2026) studied this question.
Synapse has enriched 8 closely related papers on similar clinical questions. Consider them for comparative context: